The effect of non-steroidal anti-inflammatory drugs (NSAIDs) on methotrexate (MTX) dosage, corticosteroid dosage, rheumatoid arthritis (RA) activity and laboratory data in MTX-treated patients with RA was investigated retrospectively. The MTX dosage was significantly increased in 67％ of the control patients, while in only 33％ of the NSAID-treated patients, MTX dosage was increased (p＜0.05). A significant reduction of corticosteroid dosage (p＜0.05) and RA activity (p＜0.01) in the control patients was observed. Changes in several laboratory data of RA patients during the observation period were similar between the two patient groups.
Introduction
Patients with rheumatoid arthritis (RA) are usually treated with a combination of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying anti-rheumatic drugs (DMARDs). The early use of DMARDs such as methotrexate (MTX) after diagnosing RA is recommended according to the recent guideline for the diagnosis and treatment of RA in Japan. 1, 2) The immunosuppressive and anti-inflammatory effects of MTX show pathological improvement of the synovial membranes in RA patients.
3) Serious adverse effects by drug interactions with MTX include interstitial pneumonia, bone-marrow suppression, infectious disease, and hepatic disorders were reported. 4, 5) In terms of MTX dosage, more than 6 mg/week accounts for 61.6％
among the fatal adverse cases reported in Japan. 5) Several NSAIDs suppress the uptake of MTX using the organic anion transporter (OAT) and multidrug resistance-associated protein by the kidney. 6) Elevated blood concentration of MTX by the administration of NSAIDs has been reported with high-dose (more than 1000 mg) MTX for the treatment of acute leukemia and malignant lymphoma. 7) MTX at a low dosage co-treated with NSAIDs for RA patients also caused cytopenia. 8) Meanwhile, it has also been reported that the interaction of MTX and NSAIDs would be insignificant if NSAIDs were used together at a low dosage of MTX. 9) Few reports have discussed the effect of anti-in ammatory drugs on MTX dosage changes. In this study, we retrospectively investigated the effect of NSAIDs on MTX dosage changes in RA patients. Because corticosteroids are used together in most RA patients during MTX treatment, the dosage change in corticosteroids was also investigated.
Disease Activity Score 28-c-reactive protein (DAS 28-CRP) 10 ) is one of the most popular indicator of RA activity, therefore we chose DAS 28-CRP as the index of RA activity in this study. As the index of adverse effects, the laboratory data of these patients were also monitored during combination therapy. 
Materials and Methods

Subjects and study period
Investigated items
We investigated the following items during the administration of MTX to RA patients. 
Statistical analysis
The RA treatment period was expressed as the median, and other patient characteristic parameters were expressed as the mean±standard deviation. The MTX dosage, corticosteroid dosage, DAS 28-CRP and the laboratory data were expressed as the mean±standard deviation. The ratio of patients whom MTX dosage increased between the start of administration and the end of observation were compared using the chi-square test between two groups. The others were compared using Student' s t-test. The level of signicance was p＜0.05.
Results
Patient characteristics
The characteristics of RA patients investigated are shown in Table 1 . The RA treatment period 
���ect o� �S�I�s on MT� dosage� cor� ���ect o� �S�I�s on MT� dosage� cor� ticosteroid dosage and ��S 28�CRP in R� patients
The dosage of MTX was markedly increased from the start of administration (3.8±0.7 mg/ week) to the end of observation (5.7±1.7 mg/ week) in the control group (p＜0.01). In contrast, the dosage of MTX in the NSAID group was slightly increased from the start of administration (4.0±1.2 mg/week) to the end of observation (4.8 ±1.7 mg/week) (p＜0.05) ( Table 2 ). In the control group, a marked increase in MTX dosage was observed in the RA stage II, III and IV. The ratio of patients with an increased MTX dosage was 67％ (34/51) in the control group, as compared with 33％ (6/18) in the NSAID group (p＜0.05).
The proportion of patients for whom an increase of the MTX dosage was necessary in the NSAID group was therefore one half of the control group.
Corticosteroid dosage was insignificantly changed at the end of observation in the NSAID group, while there was a signi cant dosage reduction of corticosteroids in the control group (p＜ 0.05) ( the end of observation in the NSAID group, while there was a signi cant reduction of DAS 28-CRP in the control group (p＜0.01) ( Table 2) . Especially, a marked decrease in DAS 28-CRP was observed in the RA stage III of the control group.
Changes in laboratory data in R� pa�
Changes in laboratory data in R� pa� tients 12) There are other reports that corticosteroid dosage was reduced during MTX treatment in RA patients. [13] [14] [15] In the treatment guideline of RA, the steroid dosage is gradually reduced by 1 mg every 1 to 2 months, when the control of RA activity is stable.
1)
These results indicate a decrease of the corticosteroid dosage during MTX treatment. not cause such serious symptoms from the start to the end of the observation period between the two groups. The laboratory data of these patients were insigni cant differences during the 30 months observation period.
We evaluated the correlation of DAS 28-CRP, MTX and corticosteroid dosage classified into two groups, respectively ( Table 4) When NSAIDs were previously prescribed to RA patients, the increase in MTX dosage could be avoided. It was suggested that NSAIDs treatment with MTX could control the RA activity without increasing MTX dosage, since it was reported that increased MTX dosage was related to adverse effects in RA patients. 5) In RA patients, the percentage of treatment combination with biological medicines such as etanercept and MTX for the induction of remission was gradually increased. 18, 19) We will investigate the effect of etanercept on the dosage of MTX in the future. Recently, the MTX dosage was revised to increase the maximum dosage of MTX in RA from 8 mg/week to 16 mg/week in Japan. 20) Pharmacists should pay attention to the possibility of new drug interactions due to the increased MTX dosage.
